Skip to content

Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India

Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06054451
Acronym
PSVD-India
Enrollment
210
Registered
2023-09-26
Start date
2023-08-01
Completion date
2024-06-30
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Budd-Chiari Syndrome, Non-Cirrhotic Portal Fibrosis, Non-Cirrhotic Portal Hypertension, Portal Hypertension, Porto-Sinusoidal Vascular Diseases, Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic

Keywords

Porto-sinusoidal vascular disease, Budd Chiari Syndrom, extrahepatic portal venous obstruction, Portal Hypertension, Non-Cirrhotic Portal Fibrosis

Brief summary

There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario. We intend to identify the patient cohorts who have been diagnosed as NCPH, NCPF, EHPVO, hepatic venous outlet tract obstruction (HVOTO), Veno-occlusive disease (VOD) and sinusoidal obstruction syndrome (SOS) based on their liver biopsy, endoscopy, HVPG, and radiology reports. These patients will be screened to find the patients who fit the diagnosis of PSVD. It is important to establish whether the new definition of PSVD is relevant to the Indian population and establish the usefulness of invasive tests like liver biopsy in diagnosing the disease. The patient cohorts meeting diagnosis of INCPH will be compared with those meeting the new diagnosis of PSVD. The investigators will describe the clinical (demographic, clinical risk factors, socioeconomic status), etiological (associated conditions, coagulation disorders medication use, genetic risk factors), imaging (based on ultrasound Doppler imaging or cross- sectional imaging), endoscopic, fibrosis tests (using non-invasive tests), and the histopathology of the patients who fulfil the criteria of PSVD.

Detailed description

Portal hypertension is clinically characterized by a portal venous pressure gradient between the inferior vena cava and the portal vein is more than 5 mm. Liver cirrhosis remains the leading cause of portal hypertension in the western world. However, there are conditions where portal hypertension can even occur without liver cirrhosis, referred to as Noncirrhotic portal hypertension (NCPH). The term NCPH has been derived from a variety of histopathological entities such as hepatoportal sclerosis, noncirrhotic portal fibrosis, nodular regenerative hyperplasia, or incomplete septal fibrosis. In the absence of other causes of cirrhosis and portal venous thrombosis, the condition is termed idiopathic noncirrhotic portal hypertension. The histopathological findings of INCPH are not entirely specific to portal hypertension, similar changes can be seen in patients without portal hypertension. Therefore the term Porto-sinusoidal vascular disorder(PSVD) has been recently introduced to define a group of liver vessel disorders affecting the portal venules and sinusoids irrespective of the absence or presence of liver cirrhosis. This disease entity can have a varied clinical presentation and histological findings and has been associated with several immunological and systemic disorders. Porto-sinusoidal vascular disease - Currently, for clinical practice, the VALDIG group has given a working definition for PSVD. Liver biopsy ≥20mm without cirrhosis with either 1 specific sign of portal hypertension OR 1 specific histological finding for PSVD OR Liver biopsy ≥20mm without cirrhosis with 1 sign not specific for portal hypertension AND 1 sign not specific for PSVD

Interventions

None listed

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients of 12-70 years, either gender with clinical, pathological radiological diagnosis of NCPH

Exclusion criteria

* Any patients having Cirrhosis based on clinical, pathological, or radiological diagnosis * Any patients having active malignancy

Design outcomes

Primary

MeasureTime frameDescription
To describe the clinical presentation of patients with a diagnosis of PSVD.Day 0Listing clinical presentation (signs and symptoms) of patients with PSVD (variceal bleeding, pain, ascites, sensation of lump, etc)

Secondary

MeasureTime frameDescription
Radiological description of patients with PSVD based on Doppler UltrasoundDay 0Radiological assessment will be done at baseline for characterization of changes of portal vein, small hepatic veins, liver and splenic morphology. Doppler of the portal vessels.
Histopathological features and subtypes of the PSVD spectrum in patients from India with assessment of parenchyma, vessels, portal triad and fibrosisDay 0To classify the PSVD based on the histological finding the disease.
Radiological description of patients with PSVD based on CT venographyDay 0Radiological assessment will be done at baseline for characterization of changes of portal vein, small hepatic veins, liver and splenic morphology. Doppler of the portal vessels.
Change in biomarkers like Factor VIII Ag or vWF in diagnosis of PSVDDay 0To look for the trend of non-invasive techniques in PSVD such as coagulation parameters, and inflammatory biomarkers in patients of PSVD
Presence of varices and other endoscopic findings in patients with PSVDDay 0To look for esophageal varices and portal hypertensive gastropathy
Ratio of liver stiffness and splenic stiffness using transient elastography in diagnosis of PSVDDay 0To look for the trend of non-invasive techniques in PSVD such as ARFI, transient elastography, coagulation parameters, and inflammatory biomarkers in patients of PSVD

Countries

India

Contacts

Primary ContactDr Madhumita Premkumar, DM
drmadhumitap@gmail.com7087003409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026